ValVention, Inc. Company Profile

Background

ValVention, Inc., established in 2018, is dedicated to mitigating structural heart disease through the development of next-generation transcatheter heart valves and minimally invasive cardiac support technologies. The company's mission is to address unmet clinical needs in valvular heart disease and reduce the burden of heart failure diseases. Operating within the medical device industry, ValVention focuses on innovative solutions that enhance patient outcomes and advance cardiovascular care.

Key Strategic Focus

ValVention's strategic focus centers on the development of advanced cardiovascular devices that offer minimally invasive treatment options for patients with structural heart diseases. The company's core objectives include:

Transcatheter Heart Valves: Developing next-generation transcatheter aortic valve replacement (TAVR) systems, such as the FoldaValve™, which features a unique folding mechanism to minimize delivery size and protect valve leaflets during implantation.

Minimally Invasive Cardiac Support: Creating devices like HelixCardia™, a percutaneously implantable cardiac support device inspired by the helical arrangement of myocardial fibers, designed to assist patients with advanced heart failure without direct contact with circulating blood.

By leveraging proprietary technologies and focusing on patient-centric solutions, ValVention aims to address the growing demand for less invasive and more effective treatments in the cardiovascular field.

Financials and Funding

ValVention has secured funding to support its research and development initiatives. Notably, the company received a Small Business Innovation Research (SBIR) Phase I grant from the National Heart, Lung, and Blood Institute (NHLBI) in 2022, amounting to $349,309. This grant was awarded to advance the FoldaValve™ technology, focusing on its unique leaflet-sparing mechanism and intravascular ultrasound (IVUS)-guided delivery system.

Additionally, in November 2022, the National Institutes of Health (NIH) awarded ValVention $350,000 to validate the effectiveness of the FoldaValve™ TAVR system. This funding supports studies comparing the patented sheathed inverse folding mechanism of FoldaValve™ to standard crimping methods, aiming to demonstrate enhanced durability and structural integrity.

The capital raised is intended to further the development and commercialization of ValVention's innovative cardiovascular devices, bringing them closer to market availability.

Pipeline Development

ValVention's product pipeline includes several key candidates:

FoldaValve™: A next-generation TAVR system featuring a unique folding mechanism that minimizes delivery size to a true 14-Fr, protecting valve leaflets from damage during implantation. The system is equipped with the Ingenuity™ IVUS-guided delivery system, allowing for precise positioning, repositioning, and retrieval if necessary.

HelixCardia™: A percutaneously implantable cardiac support device inspired by the helical arrangement of myocardial fibers. HelixCardia™ operates without direct contact with circulating blood, eliminating the need for blood-thinning medications and reducing risks associated with stroke and bleeding. It is designed for patients with advanced heart failure who may not tolerate major open-chest surgery.

A-Valve™: A modular transcatheter mitral valve system designed to accommodate varying patient anatomies and diseases. A-Valve™ offers different sizes of atrial stents and valves that can be assembled in the catheterization lab based on the physician's decision, providing flexibility and customization for individual patients.

These products are in various stages of development, with ongoing research and validation studies supported by recent funding.

Technological Platform and Innovation

ValVention distinguishes itself through its proprietary technologies and innovative approaches:

FoldaValve™ Technology: Utilizes a patented sheathed inverse folding mechanism that spares valve leaflets from severe crimping, preserving their structural integrity and potentially enhancing durability. The system's 14-Fr delivery size is among the smallest available, facilitating less invasive procedures.

Ingenuity™ IVUS-Guided Delivery System: An intravascular ultrasound-guided system integrated into FoldaValve™, providing real-time imaging during implantation. This technology allows for precise positioning, repositioning in six degrees of freedom, and retrieval if necessary, improving procedural outcomes and safety.

HelixCardia™ Design: Inspired by the natural helical structure of myocardial fibers, HelixCardia™ mimics the heart's twisting and untwisting motions, offering energy-efficient cardiac support without direct blood contact. This design reduces the need for anticoagulation therapy and associated risks.

These innovations position ValVention at the forefront of minimally invasive cardiovascular device development.

Leadership Team

ValVention's leadership comprises experienced professionals in cardiovascular research and medical device development:

Dr. Arash Kheradvar: Founder, President, and Chief Executive Officer. Dr. Kheradvar is a Professor at the University of California, Irvine, with over 15 years of research focused on valvular heart disease and heart failure. He has led the development of ValVention's core technologies and continues to drive the company's strategic vision.

Ronn Hosmer: Vice President of Research and Development for Heart Valves and Principal Investigator for NIH-funded projects. Mr. Hosmer brings extensive experience in cardiovascular device development and has been instrumental in advancing the FoldaValve™ system.

Daryl Chau: Project Engineer. Mr. Chau contributes to the technical development and testing of ValVention's product pipeline, ensuring engineering excellence and compliance with regulatory standards.

The leadership team's combined expertise supports ValVention's mission to innovate and improve cardiovascular care.

Competitor Profile

Market Insights and Dynamics

The global market for transcatheter heart valves and minimally invasive cardiac support devices is experiencing significant growth, driven by increasing prevalence of valvular heart diseases and heart failure, aging populations, and advancements in medical technology. The transcatheter aortic valve replacement (TAVR) market, in particular, is projected to expand substantially, with procedures expected to increase from approximately 163,000 in 2020 to around 289,000 by 2025.

Competitor Analysis

ValVention operates in a competitive landscape alongside several key players:

Edwards Lifesciences: A leading manufacturer of heart valve systems, including the SAPIEN series of transcatheter heart valves. Edwards is known for its extensive clinical experience and established market presence.

Medtronic: Offers the CoreValve and Evolut series of transcatheter aortic valves, emphasizing minimally invasive solutions and broad patient applicability.

Boston Scientific: Develops the LOTUS Edge valve system, focusing on precise positioning and retrievability during TAVR procedures.

ValVention differentiates itself through its unique technologies, such as the FoldaValve™'s leaflet-sparing mechanism and the HelixCardia™'s bloodless operation, addressing specific clinical needs unmet by existing products.

Strategic Collaborations and Partnerships

ValVention has engaged in strategic collaborations to advance its technologies:

National Institutes of Health (NIH): Secured multiple grants to support the development and validation of the FoldaValve™ system, facilitating critical research and development activities.

University of California, Irvine (UCI): Leveraged resources and research support from UCI, including Proof of Product grants from the UCI Beall Applied Innovation, to advance technologies like A-Valve™ and HelixCardia™.

These partnerships enhance ValVention's research capabilities and accelerate the path to commercialization.

Operational Insights

ValVention's strategic considerations include:

Market Positioning: Focusing on unmet clinical needs by offering devices with unique features, such as reduced delivery profiles and bloodless operation, to differentiate from competitors.

Regulatory Strategy: Engaging with regulatory bodies early in the process to ensure compliance and streamline product development and approval timelines.